Description: On January 13, 2026, IDEXX Laboratories announced that Michael (Mike) Erickson, PhD, will become President and CEO on May 12, 2026, as current President and CEO Jonathan (Jay) Mazelsky moves to Executive Chair before retiring after the May 2027 shareholder meeting. Erickson’s elevation from leading IDEXX’s Global Point of Care Diagnostics and Telemedicine businesses to the top role signals continuity in focusing on advanced diagnostic solutions and healthcare technology innovation. We’ll now...

Description: Dow Jones retail giant Amazon is approaching a fresh buy point, as the stock market holds near record highs.

Description: WESTBROOK, Maine, January 13, 2026--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the promotion of Michael (Mike) Erickson, PhD, to President and Chief Executive Officer, effective May 12, 2026, at which time Jonathan (Jay) Mazelsky, President and CEO, will transition to the role of Executive Chair of IDEXX’s Board of Directors (the "Board"). Mr. Mazelsky has announced his intention to retire from the Company immediately following the Comp

Description: Fundsmith, an investment management firm based in London, has released its annual 2025 investor letter for its “Fundsmith Equity Fund.” A copy of the letter can be downloaded here. The fund focuses on investing in equities globally. The T Class Accumulation shares where the firm invested returned 0.8% in 2025, compared to 12.8% for the […]

Description: RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Description: If you are wondering whether IDEXX Laboratories is still fairly priced after a strong run, this article walks through what the current share price could mean for long term investors. The stock last closed at US$713.35, with returns of 6.5% over the past week, 0.8% over the past month, 6.5% year to date, 70.6% over 1 year, 48.9% over 3 years, and 45.7% over 5 years. Recent coverage around IDEXX has focused on how its position in veterinary diagnostics and related services fits into long term...

Description: Idexx stock is starting the year strong as Wall Street remains bullish the animal diagnostics company.

Description: WESTBROOK, Maine, January 09, 2026--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.

Description: Dublin, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The "Veterinary Infectious Disease Diagnostics Market - A Global and Regional Analysis: Focus on Technology, Product, Animal Type, Infection Type, End user, Country, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.One of the key drivers of the veterinary infectious disease diagnostics market is the rising prevalence of zoonotic diseases. Zoonotic diseases those transmitted from animals to humans pose sig

Description: Futures fell. Lockheed Martin and other defense giants jumped on Trump's proposed $1.5 trillion "Dream Military" budget.

Description: The S&P 500 and Dow reversed from highs Wednesday, while the Nasdaq pared gains. Eli Lilly and Google flashed buy signals.

Description: IDXX shares surge 64.7% in a year as CAG Diagnostics momentum, strong retention and expanding software adoption fuel growth across regions.

Description: IDEXX Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings increase.

Description: Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...

Description: NVIDIA, IDXX and Microsoft shine on ESG metrics, fueling investor interest with strong returns and ambitious 2030 goals.

Description: Veracyte stands out in a pressured medical instruments industry as genAI adoption and rising sales forecasts fuel investor interest.

Description: Here is how Idexx Laboratories (IDXX) and Artivion (AORT) have performed compared to their sector so far this year.

Description: VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.

Description: Paramount Skydance (PSKY), Intel (INTC), and Estée Lauder (EL) are just some of the S&P 500 (^GSPC) components that gained in 2025, rebounding from negative returns in 2024. Yahoo Finance Markets and Data Editor Jared Blikre, who also hosts Yahoo Finance's Stocks in Translation podcast, takes a closer look at some of 2025's best comebacks. Catch more Stocks in Translation, with new episodes every Tuesday and Thursday. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Boosted by solid growth and clear demand among the best mutual funds, Idexx stock has blasted out into buy range.

Description: In the last year, many IDEXX Laboratories, Inc. ( NASDAQ:IDXX ) insiders sold a substantial stake in the company which...

Description: IDEXX Laboratories recently reported third-quarter 2025 earnings per share of $3.40, up over one-fifth year over year and ahead of expectations, while raising its full-year 2025 guidance for both revenue and earnings growth. The upside was powered by strong performances in the Companion Animal Group and Livestock, Poultry and Dairy segments, highlighting the value of recurring diagnostic revenues and expanding international operations even as some investors remain watchful of debt levels and...

Description: Today we're going to take a look at the well-established IDEXX Laboratories, Inc. ( NASDAQ:IDXX ). The company's stock...

Description: IDXX surges 75.6% YTD as strong CAG Diagnostics momentum and high-demand software solutions fuel growth.

Description: Although IDEXX Laboratories has outperformed the healthcare sector over the past year, analysts remain cautiously optimistic about the stock’s prospects.

Description: Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: As the Nasdaq holds tough after a five-day win streak, Google stock, Robinhood and others land on list of stocks to watch.

Description: Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Description: IDEXX Laboratories (IDXX) has caught the attention of investors after a recent shift in its stock performance. The company’s shares have seen changes over the past month, which has sparked fresh conversations about its current valuation and growth prospects. See our latest analysis for IDEXX Laboratories. Momentum has clearly been building for IDEXX Laboratories, with the share price delivering an impressive 19.95% return over the last month and a notable year-to-date share price return of...

Description: Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Description: Idexx (IDXX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Description: Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Description: IDEXX Laboratories has considerably outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Description: The consensus analyst price target for IDEXX Laboratories has recently increased from $702.17 to $754.83. This underscores renewed optimism following a strong quarterly report and an improved outlook for 2025. The uptick reflects analysts’ confidence in the company’s growth prospects and effective management execution. Stay tuned to learn the key factors driving these price target updates and how you can remain informed as the narrative continues to evolve. Stay updated as the Fair Value for...

Description: Bruker stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 68 to 72.   Can You Really Time The Stock Market? This proprietary rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.

Description: When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Description: The steep increase in pet healthcare costs have doubled over the past five years, according to NPR. There are a number of reasons for this trend, but the overall numbers are large, reaching $39.8 billion in 2024. Some projections estimate that pet healthcare will swell to $112 billion by 2030. As a result, veterinary healthcare ... Pet Healthcare Spending Is Soaring. These 5 Stocks Are Positioned to Clean Up

Description: Baron Funds, an investment management company, released its “Baron Asset Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities continued the previous quarter’s rally in the third quarter of 2025. The expectation of the Federal Reserve (the Fed) to cut interest rates was the primary driver behind the […]

Description: IDEXX Laboratories recently reported strong third-quarter results, with revenue of US$1,105.24 million and net income of US$274.61 million, as well as raising its full-year 2025 revenue and EPS guidance on the back of robust growth in Companion Animal Diagnostics and successful new product launches. The company also completed a buyback tranche repurchasing 411,180 shares for US$241.57 million in the quarter, highlighting continued commitment to capital returns amid expanding margins and...

Description: A week ago, IDEXX Laboratories, Inc. ( NASDAQ:IDXX ) came out with a strong set of quarterly numbers that could...

Description: No single month beats November for S&P 500 stock market performance. And a handful of stocks are already taking off.

Description: Baron Funds, an investment management company, released its “Baron Focused Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund delivered strong results in the third quarter, appreciating 4.83% (Institutional Shares); however, the performance underperformed the Russell 2500 Growth Index’s (the Benchmark) 10.73% gain. The fund’s underperformance stemmed […]

Description: Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.

Description: Companies in The News Are: SPR,ON,III,IDXX

Description: When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Description: When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?

Description: Shares of Zoetis slumped Tuesday after the animal healthcare company reported weaker-than-expected quarterly revenue and slashed its full-year outlook. The company posted adjusted earnings of $1.70 a share for the third quarter, above analysts’ consensus estimates of $1.62. Zoetis saw a particularly steep decline in revenue for its swine and poultry medicines.

Description: IDEXX Laboratories (IDXX) caught extra attention after releasing third-quarter results that showed healthy year-over-year gains in both revenue and net income. The company raised its full-year outlook, which signals ongoing growth. See our latest analysis for IDEXX Laboratories. Riding a wave of strong earnings and an upbeat full-year outlook, IDEXX Laboratories saw its share price surge nearly 15% in a single day and climb over 76% year-to-date. This performance has cemented its status as a...

Description: IDEXX Laboratories' stock narrative has seen a notable shift recently, as analysts update their outlook and raise the fair value price target from $679.92 to $702.17. This reflects growing confidence in business performance. This upward revision comes amid constructive sentiment around strengthening core revenue drivers and expanding opportunities in key markets. Stay tuned to find out how these changes could shape future perspectives and how you can keep informed on evolving analyst...

Description: The Morning Bull - US Market Morning Update Tuesday, Nov, 4 2025 US stock futures are sliding premarket as investors digest hawkish signals from the Federal Reserve and ongoing signs of strain in the manufacturing sector. With Fed officials making it clear that a December rate cut is not guaranteed, and manufacturing data painting a mixed, uncertain picture, market sentiment is becoming more cautious as investors weigh the impact of elevated yields and weaker production on broader economic...

Description: IDEXX Laboratories (IDXX) posted a net profit margin of 24.4% for the latest period, up from 22.3% last year, and achieved earnings growth of 16.6% that outpaced its 5-year average of 10.3%. While revenue is forecast to grow at 8.2% per year and earnings at 9.2% per year, both figures trail the broader US market expectations of 10.5% and 16.1% respectively. Investors may be encouraged by the company’s improved profitability and consistent quality of earnings, even as forward growth is set to...

Description: The first trading day of November began on an upbeat note but ended with a mixed finish, thanks to news on SNAP aid and the S&P 500 rallying after exceeding earnings reports in various sectors. The S&P 500 was up 0.2%, led by gains from numerous deals from Amazon.The tech-heavy Nasdaq ...

Description: IDEXX Laboratories (NASDAQ: IDXX) extended its streak of earnings beats this morning, reporting Q3 results that topped both EPS and revenue expectations while raising full-year guidance. The stock was trading near $656 in early action after the pre-market announcement, holding steady as investors digested the results and prepared for the company’s earnings call at 8:30 ... IDEXX Laboratories Jumps 15% on Q3 Earnings Beat

Description: Investors were barking for some shares thanks to a better-than-expected earnings report.

Description: The Nasdaq Composite and the S&P 500 advanced in an overall mixed session on Monday, with Amazon.com

Description: US equity indexes traded mixed at Monday's close as Amazon.com's (AMZN) $38 billion deal with the Mi

Description: The Dow Jones index fell but Amazon surged on deal with OpenAI. Kimberly-Clark plunged on the stock market today. Palantir popped.

Description: Idexx Laboratories catapulted to a record high Monday after the vet diagnostics outlet beat quarterly forecasts and boosted its 2025 outlook.

Description: US equity indexes closed mixed on Monday, bolstered by a surge in Amazon.com's (AMZN) shares followi

Description: IDEXX Laboratories Inc (IDXX) reports a robust 13% revenue increase and raises full-year outlook, driven by strong demand in CAG Diagnostics and strategic international expansion.

Description: US benchmark equity indexes were mostly higher after midday Monday amid a jump in Amazon.com (AMZN)

Description: US equity indexes traded mixed after midday Monday as Amazon.com's (AMZN) $38 billion deal with the

Description: Idexx Laboratories was the top performer in the on Monday after the veterinary medicine company reported better-than-expected earnings and boosted its full-year outlook. The Westbrook, Maine-based company posted adjusted earnings of $3.22 a share for the third quarter, ahead of analysts’ consensus estimates of $3.12. Idexx stock rose 16% to $729.04, putting it on pace for an all-time closing high, according to Dow Jones Market Data.

Description: Participating in the call this morning are Jay Mazelsky, President and Chief Executive Officer, Andrew Emerson, Chief Financial Officer, and John Ravis, Vice President, Investor Relations. IDEXX Laboratories, Inc. would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today.

Description: Today we're going to take a look at the well-established IDEXX Laboratories, Inc. ( NASDAQ:IDXX ). The company's stock...

Description: The benchmark US stock measures were tracking in the green before the opening bell Monday as traders

Description: WESTBROOK, Maine (AP) — Idexx Laboratories Inc. IDXX) on Monday reported third-quarter profit of $274.6 million. On a per-share basis, the Westbrook, Maine-based company said it had profit of $3.40.

Description: WESTBROOK, Maine, November 03, 2025--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results.

Description: Markets look set to enter the fifth full week of a US government shutdown as investors parse Powell's comments, news of a trade deal between Washington and Beijing, and another mammoth week of earnings.

Description: Pre-Market Futures: The futures are trading higher on this Halloween Friday, following a rollercoaster day on Wall Street that ultimately saw all the major indices finish in the red, with the NASDAQ taking the biggest hit, down 1.58% on Thursday. For much of the day, the Dow Jones Industrials were up big on the reports ... Here Are Friday’s Top Wall Street Analyst Upgrades and Downgrades: Apple, Comcast, Roblox, Zscaler and More

Description: Apple upgraded, Comcast downgraded: Wall Street's top analyst calls

Description: It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Description: Besides Wall Street's top-and-bottom-line estimates for Idexx (IDXX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Description: PROCEPT BioRobotics (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Description: TECH's Q1 results could reflect steady Protein Sciences growth but pressure in Spatial Biology amid NIH and biotech funding uncertainty.

Description: Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their momentum that began in early April, reaching new all-time highs in the third quarter. The Mid Cap Composite returned -3.2% net-of-fees in the third quarter, compared to a 2.8% gain […]

Description: HOLX vs. IDXX: Which Stock Is the Better Value Option?

Description: IDEXX Laboratories has recently seen its Fair Value Estimate decrease from $695.09 to $679.92. This reflects a modest downward adjustment in the company’s projected value. This change comes as revenue growth expectations are slightly tempered, even as the company continues to deliver strong performance in key business areas. Stay tuned to discover how these nuanced adjustments shape the evolving narrative for IDEXX Laboratories and what you can do to keep informed as the story develops. What...